Hypometabolism of the posterior parietal cortex in Parkinson’s disease with mild cognitive impairment predicts the conversion to dementia: 5-year longitudinal observations
Objective: To investigate the neuroimaging marker that predict the conversion of mild cognitive impairment (MCI) to dementia in Parkinson’s disease (PD) patients. Background: Patients with…The role of exposure to pesticides in the etiology of Parkinson’s disease: F-DOPA positron emission tomography study
Objective: To examine the pattern of ligand uptake on F-DOPA PET in patients with PD who were exposed or not exposed to pesticides and examine…Relation of asymmetry of dopamine depletion with motor or non-motor symptoms in patients with Parkinson’s disease: A pilot study
Objective: This study was aimed to investigate whether asymmetry of dopamine depletion through dopamine transporter (DAT) imaging is associated with motor or non-motor symptoms in…Specific Metabolic Brain Networks Associated with Parkinsonian and Cerebellar Variants of Multiple System Atrophy
Objective: To identify specific metabolic brain networks for parkinsonian (MSA-P) and cerebellar (MSA-C) variants of MSA. Background: MSA is associated with a disease-related metabolic brain network (MSARP)…Link between striatal dopamine uptake and cortical dysconnectivity in Parkinson’s disease
Objective: This study aims to explore pathways of reduced striatal dopamine synthesis in PD that may affect striato-cortical connectivity and implicate in altered glucose metabolism…In vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome
Objective: To assess in vivo, with molecular imaging the brain distribution of tau aggregates ([18F]AV1451 PET) and β-amyloid depositions ([18F]AV45 PET) in patients with Corticobasal…Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease
Objective: To directly compare 18F-DOPA with a highly specific dopamine transporter radioligand 11C-PE2I, for the assessment of motor severity and rate of progression in Parkinson's…PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins
Objective: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 ([11C]methylamino pyridin-3-yl buta-1,3-dienyl benzo[d]thiazol-6-ol) in tauopathies, and in conditions not…Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study
Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome
Objective: To evaluate change in AV-1451 positron emission tomography (PET) imaging in patients with Progressive Supranuclear Palsy (PSP) and Cortico-Basal Syndrome (CBS) over 9 months…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 35
- Next Page »